Crossmark

Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer

Crossref DOI link: https://doi.org/10.1007/s10637-022-01310-x

Published Online: 2022-10-13

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sumi, Toshiyuki

Koshshino, Yuta

Sekikawa, Motoki

Nagahisa, Yuta

Matsuura, Keigo

Shijubou, Naoki

Kamada, Koki

Watanabe, Hiroki

Michimata, Haruhiko

Nagayama, Daiki

Tanaka, Yusuke

Yamada, Yuichi

Chiba, Hirofumi
License Information

Text and Data Mining valid from 2022-10-13

Version of Record valid from 2022-10-13
More Information

Article History

Received: 18 August 2022

Accepted: 4 October 2022

First Online: 13 October 2022

Declarations

:

: This retrospective study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional Ethics Committee of Hakodate Goryoukaku Hospital (approval no. 2022–019) approved this study.

: Informed consent was obtained using the opt-out method.

: Not applicable.

: The authors have no relevant financial or non-financial interests to disclose.

Document is current

Any future updates will be listed below